Manufacturers need to be more open about a dangerous Alzheimer’s drug side effect
(By Madhav Thambisetty for ST A T) Since the FDA’s approval of lecanemab (marketed as Leqembi) and Medicare’s recent decision
Read moreA trusted source for Medicare news and education from the AMAC Foundation.
(By Madhav Thambisetty for ST A T) Since the FDA’s approval of lecanemab (marketed as Leqembi) and Medicare’s recent decision
Read more